局限性前列腺癌放疗剂量与雄激素剥夺治疗的荟萃回归分析
该荟萃回归分析纳入40项III期随机对照试验共21429例局限性前列腺癌患者,比较放疗剂量提升与雄激素剥夺治疗(ADT)强化的5年结局。结果显示单纯剂量提升未显著改善任何5年结局,而低剂量放疗联合长期ADT显著改善5年前列腺癌特异性死亡率(OR 0.34)和远处转移(OR 0.35)。
要点
- 放疗剂量提升无论是否联合短期ADT均未显著改善5年结局。
- 低剂量放疗联合长期ADT显著改善5年PCSM和DM。
- 低剂量放疗联合短期ADT也显著改善5年PCSM。
核心结论
- 与单纯增加放疗剂量相比,加用ADT对临床终点带来更一致的改善。
研究设计与样本
- 遵循PRISMA指南的荟萃回归分析,纳入40项III期随机对照试验,共21429例局限性前列腺癌患者。
主要发现
- 剂量提升在无或联合短期ADT时均未显著改善任何5年结局。
- 低剂量放疗联合长期ADT较单纯低剂量放疗显著改善5年PCSM(OR 0.34,95%CI 0.22-0.54,p<0.001)和DM(OR 0.35,95%CI 0.20-0.63,p<0.001)。
- 低剂量放疗联合短期ADT较单纯低剂量放疗显著改善5年PCSM(OR 0.55,95%CI 0.41-0.75,p<0.001)。
临床怎么用
- 在局限性前列腺癌放疗中,应重视ADT的联合应用而非单纯提升放疗剂量。
局限性
- 受研究间异质性限制,且缺乏个体患者数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While multiple randomized trials have evaluated the benefit of radiation therapy (RT) dose escalation and the use and prolongation of androgen deprivation therapy (ADT) in the treatment of prostate cancer, few studies have evaluated the relative benefit of either form of treatment intensification with each other. Many trials have included treatment strategies that incorporate either high or low dose RT, or short-term or long-term ADT (STADT or LTADT), in one or more trial arms. We sought to compare different forms of treatment intensification of RT in the context of localized prostate cancer. METHODS: Using preferred reporting items for systemic reviews and meta-analyses (PRISMA) guidelines, we collected over 40 phases III clinical trials comparing different forms of RT for localized prostate cancer. We performed a meta-regression of 40 individual trials with 21,429 total patients to allow a comparison of the rates and cumulative proportions of 5-year overall survival (OS), prostate cancer-specific mortality (PCSM), and distant metastasis (DM) for each treatment arm of every trial. RESULTS: Dose-escalation either in the absence or presence of STADT failed to significantly improve any 5-year outcome. In contrast, adding LTADT to low dose RT significantly improved 5-year PCSM (Odds ratio [OR] 0.34, 95% confidence interval [CI] 0.22-0.54, p < 0.001) and DM (OR 0.35, 95% CI 0.20-0.63. p < 0.001) over low dose RT alone. Adding STADT also significantly improved 5-year PCSM over low dose RT alone (OR 0.55, 95% CI 0.41-0.75, p < 0.001). CONCLUSION: While limited by between-study heterogeneity and a lack of individual patient data, this meta-analysis suggests that adding ADT, versus increasing RT dose alone, offers a more consistent improvement in clinical endpoints.
引用
- Jiang T, Markovic D, Patel J, et al. Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials. Prostate Cancer Prostatic Dis. 2021. PMID: 34400799. doi:10.1038/s41391-021-00432-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。